Akero Therapeutics Announces Initiation of Phase 3 Synchrony Outcomes Trial of Efruxifermin in Patients With Compensated Cirrhosis (F4) Due to Mash
Akero Therapeutics宣佈在因Mash導致的代償性肝硬化(F4)患者中啓動Efruxifermin的第3期同步結果試驗。
Akero Therapeutics Announces Initiation of Phase 3 Synchrony Outcomes Trial of Efruxifermin in Patients With Compensated Cirrhosis (F4) Due to Mash
Akero Therapeutics宣佈在因Mash導致的代償性肝硬化(F4)患者中啓動Efruxifermin的第3期同步結果試驗。
譯文內容由第三人軟體翻譯。